Home  /  Resource Library  /  SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (>80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) – INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL

SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (>80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) – INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL

EHA 2023